Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.

In NHL patients, prophylactic tocilizumab resulted in higher plasma concentrations of IL-6 on days 2 and 6 after CAR-T cell infusion, although the difference compared to patients treated without prophylaxis did not reach statistical significance (Supplementary Fig. 5 ).

also in 111,027 other papers